Pomerantz Law Firm Announces Class Action Lawsuit Against Regeneron Pharmaceuticals for Securities Fraud

Class Action Lawsuit Filed Against Regeneron Pharmaceuticals

Pomerantz LLP, a law firm with a storied history in securities litigation, has announced the initiation of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN). The lawsuit seeks to represent investors who incurred financial losses due to alleged violations of securities laws by Regeneron and its corporate officials. This legal action serves as a significant reminder for investors about the importance of their rights when facing corporate misconduct.

Background of the Case

Investors are being urged to contact Pomerantz LLP as they navigate the complexities of this class action. Those who purchased or acquired Regeneron’s securities during the defined class period may have until September 14, 2026, to petition the Court for appointment as Lead Plaintiff. Interested parties can reach out via email or telephone to secure their place in this class action.

The allegations stem from recent announcements by Regeneron that have raised serious concerns over the integrity of its clinical trials. On April 29, 2026, during a quarterly earnings call, the company acknowledged changes made to their Phase III Fianlimab-Libtayo Study, including an unexpected alteration in the patient eligibility criteria. Following this revelation, Regeneron's stock plummeted by over 6%, decreasing from $731.77 to $686.36 per share.

This downward trend accelerated following a later announcement on May 15, 2026, when the company confirmed that the trial had failed to meet its primary endpoint of improved progression-free survival (PFS). This shocking news resulted in a further decline of 9.82% in stock value, bringing the price down to $629.68 per share by May 16, 2026. Such volatility has raised eyes within the investment community, prompting investigations and further scrutiny of Regeneron's business practices.

The Role of Pomerantz LLP

Pomerantz LLP, renowned for its expertise in corporate, securities, and antitrust class litigation, is spearheading this legal challenge. Founded over 85 years ago by Abraham L. Pomerantz, considered a pioneer of securities class actions, the firm boasts a legacy of fighting for investor rights. With a record of recovering substantial damages for its clients, Pomerantz is positioned as an important ally for those seeking justice in the face of corporate wrongdoing.

Potential class members can obtain a copy of the formal complaint and gain further insights into the process through the firm's website, www.pomerantzlaw.com. This empowerment of investors is crucial during a time when corporate ethics and accountability are under increasing scrutiny.

Conclusion

The class action lawsuit against Regeneron Pharmaceuticals highlights the crucial role that legal action plays in holding companies accountable for their business operations. As investors evaluate their positions, it’s essential to consider the implications of corporate announcements and the significance of seeking legal recourse when necessary. Pomerantz LLP’s announcement serves as a vital reminder for investors to be vigilant and proactive in protecting their investments.

For those interested, contacting Danielle Peyton at Pomerantz LLP is the first step toward taking action in this important legal battle. Prompt decisions could lead to greater stakes in the future resolution of this class action lawsuit.